ファーマコゲノミクス市場：製品、技術、適応症、用途別-2025-2030年の世界予測

ファーマコゲノミクス市場は、2023年に40億6,000万米ドルと評価され、2024年には44億8,000万米ドルに達すると予測され、CAGR 10.54％で成長し、2030年には82億米ドルになると予測されています。

ファーマコゲノミクスは、遺伝子が人の薬物反応にどのように影響するかを研究するもので、個人の遺伝子構成に合わせて治療戦略を調整することで、より個別化された医療アプローチを提供します。この分野は、プレシジョン・メディシンの推進、副作用の最小化、薬効の向上に不可欠です。ファーマコゲノミクスの用途は、腫瘍学、循環器学、神経学、感染症など様々な分野に及び、製薬、診断、個別化医療企業によって利用されています。最終用途の範囲には、精密医療機能の導入や強化を目指す病院、研究機関、バイオ製薬企業が含まれます。

ファーマコゲノミクス市場は、個別化医療の必要性の高まり、薬物有害事象の増加、ゲノムシークエンシングの技術的進歩により成長しています。人工知能とビッグデータ解析の統合は、規制機関によるファーマコゲノミクスに基づいた医薬品の承認の増加と同様に、重要な潜在的機会を提示しています。こうした展望を生かすため、利害関係者は研究開発への投資、ゲノム技術企業との提携、ファーマコゲノム検査の利点と応用に関するヘルスケア専門家の教育に注力することが推奨されます。

しかし、市場は遺伝子検査費用の高騰、遺伝子のプライバシーに関する倫理的懸念、新興国地域での認知度やインフラの未整備といった課題に直面しています。また、規制上のハードルや乏しい償還の枠組みも市場の成長を阻害しています。

技術革新と研究の主な分野としては、より費用対効果の高いシーケンス技術の開発、データ解釈ソフトウェアの強化、遺伝子と薬剤の相互作用に関するエビデンスに基づく洞察を提供するための臨床試験の拡大などが挙げられます。市場はダイナミックでありながら細分化されており、新興経済諸国では支援政策や確立されたヘルスケアシステムにより大きな成長の可能性があります。ファーマコゲノミクス分野での発展を目指す利害関係者にとって、既存の課題に効率的に対処し、最先端技術を活用することは極めて重要です。

市場力学：急速に進化するファーマコゲノミクス市場の主要市場インサイトを公開

ファーマコゲノミクス市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の増加と精密医療への需要の高まり
  • ヘルスケアインフラへの投資の増加
  • 分子診断法に関連する技術の進歩
• 市場抑制要因
  • 研究開発に伴うコスト高
• 市場機会
  • 個別化医療や消費者向け遺伝子検査サービスの動向の高まり
  • ファーマコゲノミクスを改善するための研究開発活動への投資の増加
• 市場の課題
  • 認知度の低さと必要なインフラ設備

ポーターのファイブフォース：ファーマコゲノミクス市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ファーマコゲノミクス市場における外部からの影響の把握

外部マクロ環境要因は、ファーマコゲノミクス市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ファーマコゲノミクス市場における競合情勢の把握

ファーマコゲノミクス市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスファーマコゲノミクス市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ファーマコゲノミクス市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ファーマコゲノミクス市場における成功への道筋を描く

ファーマコゲノミクス市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の発症率の上昇と精密医療の需要
    • ヘルスケアインフラへの投資増加
    • 分子診断手順に関連する技術的進歩
  • 抑制要因
    • 研究開発能力に関連する高コスト
  • 機会
    • パーソナライズされた医薬品と消費者向け遺伝子検査サービスの新たなトレンド
    • 改善のための研究開発活動への投資の増加ファーマコゲノミクス
  • 課題
    • 認識と必要なインフラ設備の不足
• 市場セグメンテーション分析
  • 技術：ポリメラーゼ連鎖反応技術の進歩
  • 応用：業界を超えたファーマコゲノミクスの多様な応用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ファーマコゲノミクス市場：製品別

• 消耗品
• キットと試薬
• サービス

第7章 ファーマコゲノミクス市場：技術別

• DNA配列解析
• 電気泳動
• 質量分析
• マイクロアレイ
• ポリメラーゼ連鎖反応

第8章 ファーマコゲノミクス市場適応症別

• 神経学
• 腫瘍学
• 疼痛管理

第9章 ファーマコゲノミクス市場：用途別

• 臨床診断ラボ
• 臨床調査と創薬
• パーソナライズ医療

第10章 南北アメリカのファーマコゲノミクス市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のファーマコゲノミクス市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのファーマコゲノミクス市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • SOPHiA GENETICS、CHU de Nimesとの業務拡大を発表
  • ディアテック・ファーマコジェネティクス、腫瘍学における精密検査の進歩に向けた新たな提携を発表
  • MyRxが仮想的な薬物遺伝子検査相談の提供を開始
• 戦略分析と提言

企業一覧

• Admera Health
• Agena Biosciences Inc. by Mesa Laboratories, Inc.
• BiogeniQ Inc.
• Castle Biosciences, Inc.
• CENTOGENE N.V.
• Coriell Life Sciences
• Diatech Pharmacogenetics
• Dynamic DNA Laboratorie
• Empire Genomics by Biocare Medical
• Exceltox Laboratories
• Genelex Corporation by Invitae
• Genetworx
• Genomind
• GenXys
• Gravity Diagnostics
• Illunima Inc.
• Integra Laboratories
• Kailos Genetics by healthOme
• Myriad Genetics Inc.
• OneOme LLC
• Personalis Inc.
• Phamatech Inc. by Caris Life Sciences
• Quest Diagnostics
• Thermo Fisher Scientific Inc.
• ViennaLab Diagnostics GmbH by BioVendor Group

LIST OF FIGURES

• FIGURE 1. PHARMACOGENOMICS MARKET RESEARCH PROCESS
• FIGURE 2. PHARMACOGENOMICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PHARMACOGENOMICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PHARMACOGENOMICS MARKET DYNAMICS
• TABLE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL RESEARCH & DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. CANADA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 40. CANADA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. CANADA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. CHINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. CHINA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. CHINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. INDIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 66. INDIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. ITALY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. ITALY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. ITALY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. POLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 151. POLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. POLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 154. QATAR PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. QATAR PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. QATAR PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 194. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2023

The Pharmacogenomics Market was valued at USD 4.06 billion in 2023, expected to reach USD 4.48 billion in 2024, and is projected to grow at a CAGR of 10.54%, to USD 8.20 billion by 2030.

Pharmacogenomics is the study of how genes affect a person's response to drugs, offering a more personalized medicine approach by tailoring therapeutic strategies to individuals' genetic make-ups. This field is essential in advancing precision medicine, minimizing adverse drug reactions, and improving drug efficacy. The application of pharmacogenomics spans various areas including oncology, cardiology, neurology, and infectious diseases, and is utilized by pharmaceuticals, diagnostics, and personalized medicine companies. The end-use scope involves hospitals, research institutions, and biopharmaceutical companies seeking to implement or enhance precision medicine capabilities.

The market for pharmacogenomics is growing due to personalized medicine's increasing necessity, rising adverse drug events, and technological advancements in genomic sequencing. The integration of artificial intelligence and big data analytics presents significant potential opportunities, as does the increasing approval of pharmacogenomic-informed drugs by regulatory bodies. To capitalize on these prospects, stakeholders are recommended to invest in R&D, collaborate with genomic technology firms, and focus on educating healthcare professionals about the benefits and applications of pharmacogenomic testing.

However, the market faces challenges such as high costs of genetic testing, ethical concerns regarding genetic privacy, and a lack of widespread awareness and infrastructure in developing regions. Regulatory hurdles and scarce reimbursement frameworks also impede market growth.

Key areas for innovation and research include developing more cost-effective sequencing technologies, enhancing data interpretation software, and expanding clinical trials to provide evidence-driven insights into gene-drug interactions. The market is dynamic yet fragmented, with significant potential for growth in developed economies due to supportive policies and established healthcare systems. Efficiently addressing the existing challenges and leveraging cutting-edge technologies will be crucial for stakeholders aiming to advance in the pharmacogenomics field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmacogenomics Market

The Pharmacogenomics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of chronic diseases and demand for precision medicine
  • Increasing investments for healthcare infrastructures
  • Technological advancements associated with molecular diagnostics procedure
• Market Restraints
  • High costs associated with research and development proficiencies
• Market Opportunities
  • Emerging trend of personalized medicines and direct-to-consumer genetic testing services
  • Rising investment in R&D activities to improve pharmacogenomics
• Market Challenges
  • Dearth of awareness and required infrastructural facilities

Porter's Five Forces: A Strategic Tool for Navigating the Pharmacogenomics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmacogenomics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmacogenomics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmacogenomics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmacogenomics Market

A detailed market share analysis in the Pharmacogenomics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmacogenomics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmacogenomics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmacogenomics Market

A strategic analysis of the Pharmacogenomics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pharmacogenomics Market, highlighting leading vendors and their innovative profiles. These include Admera Health, Agena Biosciences Inc. by Mesa Laboratories, Inc., BiogeniQ Inc., Castle Biosciences, Inc., CENTOGENE N.V., Coriell Life Sciences, Diatech Pharmacogenetics, Dynamic DNA Laboratorie, Empire Genomics by Biocare Medical, Exceltox Laboratories, Genelex Corporation by Invitae, Genetworx, Genomind, GenXys, Gravity Diagnostics, Illunima Inc., Integra Laboratories, Kailos Genetics by healthOme, Myriad Genetics Inc., OneOme LLC, Personalis Inc., Phamatech Inc. by Caris Life Sciences, Quest Diagnostics, Thermo Fisher Scientific Inc., and ViennaLab Diagnostics GmbH by BioVendor Group.

Market Segmentation & Coverage

This research report categorizes the Pharmacogenomics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Consumables, Kits & Reagents, and Services.
• Based on Technology, market is studied across DNA Sequencing, Electrophoresis, Mass Spectrometry, Microarray, and Polymerase Chain Reaction.
• Based on Indication, market is studied across Neurology, Oncology, and Pain Management.
• Based on Application, market is studied across Clinical Diagnostics Labs, Clinical Research & Drug Discovery, and Personalized Medicine.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of chronic diseases and demand for precision medicine
    • 5.1.1.2. Increasing investments for healthcare infrastructures
    • 5.1.1.3. Technological advancements associated with molecular diagnostics procedure
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with research and development proficiencies
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging trend of personalized medicines and direct-to-consumer genetic testing services
    • 5.1.3.2. Rising investment in R&D activities to improve pharmacogenomics
  • 5.1.4. Challenges
    • 5.1.4.1. Dearth of awareness and required infrastructural facilities
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Advances in Polymerase Chain Reaction technique
  • 5.2.2. Application: Diverse applications of pharmacogenomics across industries
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pharmacogenomics Market, by Product

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Kits & Reagents
• 6.4. Services

7. Pharmacogenomics Market, by Technology

• 7.1. Introduction
• 7.2. DNA Sequencing
• 7.3. Electrophoresis
• 7.4. Mass Spectrometry
• 7.5. Microarray
• 7.6. Polymerase Chain Reaction

8. Pharmacogenomics Market, by Indication

• 8.1. Introduction
• 8.2. Neurology
• 8.3. Oncology
• 8.4. Pain Management

9. Pharmacogenomics Market, by Application

• 9.1. Introduction
• 9.2. Clinical Diagnostics Labs
• 9.3. Clinical Research & Drug Discovery
• 9.4. Personalized Medicine

10. Americas Pharmacogenomics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Pharmacogenomics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacogenomics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. SOPHiA GENETICS Announces Expansion of Work with CHU de Nimes
  • 13.3.2. Diatech Pharmacogenetics Announces New Collaboration to Advance Precision Testing in Oncology
  • 13.3.3. MyRx launches to provide virtual pharmacogenetic testing consultations
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Admera Health
• 2. Agena Biosciences Inc. by Mesa Laboratories, Inc.
• 3. BiogeniQ Inc.
• 4. Castle Biosciences, Inc.
• 5. CENTOGENE N.V.
• 6. Coriell Life Sciences
• 7. Diatech Pharmacogenetics
• 8. Dynamic DNA Laboratorie
• 9. Empire Genomics by Biocare Medical
• 10. Exceltox Laboratories
• 11. Genelex Corporation by Invitae
• 12. Genetworx
• 13. Genomind
• 14. GenXys
• 15. Gravity Diagnostics
• 16. Illunima Inc.
• 17. Integra Laboratories
• 18. Kailos Genetics by healthOme
• 19. Myriad Genetics Inc.
• 20. OneOme LLC
• 21. Personalis Inc.
• 22. Phamatech Inc. by Caris Life Sciences
• 23. Quest Diagnostics
• 24. Thermo Fisher Scientific Inc.
• 25. ViennaLab Diagnostics GmbH by BioVendor Group